Form 4: Zimmer Biomet Director Maria Teresa Hilado Reports Phantom Stock Unit Acquisition

Director Maria Teresa Hilado reports acquisition of phantom stock units in Zimmer Biomet Holdings, Inc. under the Deferred Compensation Plan for Non-Employee Directors.

Summary

• Maria Teresa Hilado, a director of Zimmer Biomet Holdings, Inc., filed a Form 4 to report changes in beneficial ownership.
• The report details the acquisition of phantom stock units under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
• On September 30, 2024, Hilado acquired 255.197 phantom stock units at a price of $107.76 per unit.
• These units will be settled in cash in five annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.
• Following the reported transaction, Hilado beneficially owns 8,759.52 derivative securities, which includes 17.706 phantom stock units accrued on July 31, 2024, under the dividend reinvestment provision of the plan.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing indicating standard compensation practices. It doesn't contain information that would significantly impact investor sentiment positively or negatively.

Positives

• The acquisition of phantom stock units aligns the director's interests with the long-term performance of the company.
• The dividend reinvestment provision further increases the director's stake in the company.

Future Outlook

The phantom stock units will be settled in cash in five annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.

Industry Context

Director ownership and compensation structures are common in publicly traded companies to align management and shareholder interests. Deferred compensation plans are frequently used to incentivize long-term performance.

Comparison to Industry Standards

• Deferred compensation plans for non-employee directors are a common practice among publicly traded companies, including Zimmer Biomet's competitors such as Stryker Corporation and Johnson & Johnson.
• The structure of Zimmer Biomet's plan, with cash settlement in installments after service ends, is similar to those offered by other large medical device companies to retain and incentivize board members.

Stakeholder Impact

• The acquisition of phantom stock units by a director can positively influence shareholder confidence by aligning management's interests with those of the shareholders.

Key Dates